Has Ashequl Islam, MD received payments from drug or device companies?

Yes. Drug and device makers reported $17,317 in general payments to Ashequl Islam, MD across 86 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ashequl Islam, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ashequl Islam, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ashequl Islam, MD

Interventional Cardiology · Springfield, MANPI 1538172747

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 74.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $5,684 and has fallen 52.2% since, to $2,719 in 2025.

$17,317in general payments, 2019–2025

Across 86 payments — averaging $201.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$13K
Abbott$2K
Silk Road Medical, Inc.$1K
Siemens Medical Solutions USA, Inc.$774
Edwards Lifesciences$311
Shockwave Medical, Inc$181
plus $426 from 5 others

$402,315in research payments, 2019–2025

Across 57 payments — averaging $7058.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$402K

What the payments were for

Speaking & faculty fees$8,61350%
Grants$270%
Travel & lodging$4,67227%
Food & beverage$4,00523%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic	47	$12,860
Abbott	16	$1,663
Silk Road Medical, Inc.	6	$1,102
Siemens Medical Solutions USA, Inc.	3	$774
Edwards Lifesciences	3	$311
Shockwave Medical, Inc	3	$181
Philips North America LLC	2	$178
Boston Scientific	2	$101
Alnylam Pharmaceuticals Inc.	1	$88
Cardiovascular Systems Inc.	1	$33
Cook Medical LLC	2	$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

COREVALVE EVOLUT R$8,172
CoreValve Evolut$3,500
ENROUTE Transcarotid Neuroprotection System$993
ENROUTE Transcarotid Stent System$993
ENHANCE Transcarotid Peripheral Access Kit$993
ENROUTE 0.014 Guidewire$993
TRICLIP$979
ACUSON SC2000 Diagnostic Ultrasound System$252
AMPLATZER AMULET$166
NAVITOR$150
EVOQUE$140
(6575) Coronary Undivided$110
Edwards SAPIEN 3 Transcatheter Heart Valve$106

How this compares

$17,317 in reported general payments places this provider in the 70th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$232,992

Medicare patients

1,237

Services billed

2,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	64	$53,588
EntrestoSacubitril/Valsartan	70	$52,561
FarxigaDapagliflozin Propanediol	60	$44,679
Repatha SureclickEvolocumab	41	$29,220
XareltoRivaroxaban	28	$26,799
Praluent PenAlirocumab	32	$26,509
Repatha SyringeEvolocumab	12	$4,969
Metoprolol Succinate	216	$3,553
CrestorRosuvastatin Calcium	12	$3,249
Rosuvastatin Calcium	112	$2,916
Atorvastatin Calcium	176	$2,712
Ezetimibe	37	$1,207
Lisinopril	115	$1,070
Isosorbide Mononitrate ErIsosorbide Mononitrate	72	$1,046
Amlodipine Besylate	138	$938

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Springfield

Amir LotfiSpringfield$20K
Mohammed IbrahimSpringfield$8K
Ali ElfandiSpringfield$5K
Kevin MorineSpringfield$5K
Eric SecemskyBoston$1.2M
Darshan DoshiBoston$730K
Charles GibsonBoston$661K
Duane PintoBoston$491K
Robert YehBoston$412K
Thomas PiemonteBurlington$330K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →